• The FDA placed Bright Minds Biosciences' planned US Phase 2 BMB-101 trial for developmental and epileptic encephalopathies on partial clinical hold.
• Regulators cited mouse toxicity findings and insufficient pharmacokinetic and juvenile toxicity data to support pediatric enrollment.
• The company believes the hold affects only the planned US trial, leaving other ongoing clinical trials unaffected.
• A full FDA hold letter is expected within 30 days; additional data or studies may be required to address regulatory concerns.
• There is no assurance when or whether the hold will be lifted or future US trials will proceed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bright Minds Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020730PRIMZONEFULLFEED9867742) on November 02, 2026, and is solely responsible for the information contained therein.